Featured Research

from universities, journals, and other organizations

Jefferson Researchers Show Angiostatin And Radiation Are Safe In Early Trials For Advanced Cancer

Date:
November 6, 2001
Source:
Thomas Jefferson University
Summary:
Results from early clinical studies of a highly-publicized cancer drug designed to halt tumor growth by cutting off its blood supply indicates the medication is safe when combined with radiation therapy in the treatment of advanced cancers.

Results from early clinical studies of a highly-publicized cancer drug designed to halt tumor growth by cutting off its blood supply indicates the medication is safe when combined with radiation therapy in the treatment of advanced cancers.

Related Articles


Daily doses of the drug Angiostatin, along with radiation, were given to 15 patients with advanced cancer, particularly cancers of the head and neck, prostate, breast and lung at the Kimmel Cancer Center at Thomas Jefferson University Hospital in Philadelphia. The patients didn't seem to suffer any ill effects from the treatment, other than what would normally be expected from receiving radiation, notes Adam Dicker, M.D., Ph.D., assistant professor of radiation oncology at Jefferson Medical College of Thomas Jefferson University, who led the trial along with Walter Curran, Jr., M.D., professor and chair of radiation oncology at Jefferson Medical College of Thomas Jefferson University and clinical director of Jefferson's Kimmel Cancer Center.

All patients had a partial response to the radiation and drug treatment, meaning their disease either temporarily stopped growing or regressed somewhat.

While researchers are encouraged by the initial results, they point out that the study, a Phase I clinical trial, typically tests for safety and to determine how the body handles the drug and is not necessarily aimed at measuring its effectiveness. Patients will continue to receive higher doses of Angiostatin in the coming parts of the trial.

Dr. Dicker presents his team's findings in Miami Beach October 31 at the international conference, Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications, sponsored by the American Association for Cancer Research, the National Cancer Institute and the European Organization for Research and Treatment of Cancer.

Patients received Angiostatin - an antiangiogenic drug candidate being developed by EntreMed, Inc., a Rockville, Md.-based biotechnology company - intravenously five times weekly prior to radiotherapy during a five-to-seven week period. Radiation doses were determined by the type and location of the patient's tumor. Some patients had chemotherapy prior to the study.

Dr. Dicker points out that the Angiostatin-radiation trial is one of two Phase I trials involving the drug conducted simultaneously at Thomas Jefferson University Hospital and Jefferson's Kimmel Cancer Center - the only trials of Angiostatin in the United States. The other trial found that giving Angiostatin alone to patients with advanced cancer who had failed prior chemotherapy was safe and had few side effects.

Carrying out two trials at once is a novel approach to acquire a significant amount of clinical data on a drug more quickly than usual, he notes.

Angiostatin is a protein and a natural tumor inhibitor discovered several years ago in mice in the laboratory of Harvard scientist and surgeon M. Judah Folkman, M.D. The drug works by blocking the formation of blood vessels, based on the theory that cancers cannot grow or spread without a blood supply to feed them - a process known as angiogenesis. Angiostatin is part of a class of drugs called angiogenesis inhibitors. Some researchers believe that Angiostatin and other anti-angiogenesis drugs will expand the armamentarium of drugs that will halt cancer growth, with the disease becoming more a chronic illness patients can live with.

Angiogenesis has become one of the hottest areas of cancer research.

EntreMed has been developing and testing anti-angiogenesis drugs in human clinical trials. Dozens of drugs are under development by companies all over the world.


Story Source:

The above story is based on materials provided by Thomas Jefferson University. Note: Materials may be edited for content and length.


Cite This Page:

Thomas Jefferson University. "Jefferson Researchers Show Angiostatin And Radiation Are Safe In Early Trials For Advanced Cancer." ScienceDaily. ScienceDaily, 6 November 2001. <www.sciencedaily.com/releases/2001/11/011106084759.htm>.
Thomas Jefferson University. (2001, November 6). Jefferson Researchers Show Angiostatin And Radiation Are Safe In Early Trials For Advanced Cancer. ScienceDaily. Retrieved March 2, 2015 from www.sciencedaily.com/releases/2001/11/011106084759.htm
Thomas Jefferson University. "Jefferson Researchers Show Angiostatin And Radiation Are Safe In Early Trials For Advanced Cancer." ScienceDaily. www.sciencedaily.com/releases/2001/11/011106084759.htm (accessed March 2, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Monday, March 2, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Treadmill Test Can Predict Chance Of Death Within A Decade

Treadmill Test Can Predict Chance Of Death Within A Decade

Newsy (Mar. 2, 2015) Johns Hopkins researchers analyzed 58,000 heart stress tests to come up with a formula that predicts a person&apos;s chances of dying in the next decade. Video provided by Newsy
Powered by NewsLook.com
Going Gluten-Free Could Get You A Tax Break

Going Gluten-Free Could Get You A Tax Break

Newsy (Mar. 2, 2015) If a doctor advises you to remove gluten from your diet, you could get a tax deduction on the amount you spend on gluten-free foods. Video provided by Newsy
Powered by NewsLook.com
GlaxoSmithKline and Novartis Try Swapping Success

GlaxoSmithKline and Novartis Try Swapping Success

Reuters - Business Video Online (Mar. 2, 2015) GlaxoSmithKline and Novartis have completed a series of asset swaps worth more than $20 billion. As Grace Pascoe reports they say the deal will reshape both drugmakers. Video provided by Reuters
Powered by NewsLook.com
How Can West Africa Rebuild After Ebola?

How Can West Africa Rebuild After Ebola?

Reuters - Business Video Online (Mar. 2, 2015) How best to rebuild the three West African countries struggling with Ebola will be discussed in Brussels this week. As Hayley Platt reports Sierra Leone has the toughest job ahead - its once thriving economy has been ravaged by the disease. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins